SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Research

Read more breaking news

 

 

Medical Nutrition: RCT finds little benefit from fish oil for fistula failure

Post a commentBy Eliot Beer , 20-Feb-2017

Medical Nutrition: RCT finds little benefit from fish oil for fistula failure

Fish oil supplementation may have no benefit in preventing the failure of fistulas in dialysis patients, with a failure rate similar to placebo, a new RCT suggests.

The FAVOURED study looked at the potential effectiveness of both fish oil and aspirin in preventing the failure of arteriovenous fistulas (AVF) in dialysis patients, after previous studies suggested their benefit for dialysis patients receiving grafts.

Fistulas are artificial veins, often in the arm, created to provide access for dialysis in patients with kidney disease. They are preferred over grafts, but have a longer maturation time and a significantly higher risk of early failure (20-50%), said the FAVOURED researchers - led by Dr Ashley Irish from Fiona Stanley Hospital in Australia.

Fish oil has been shown to increase patency rates in [grafts], but it has not been assessed in AVFs,” they said.

Writing in JAMA Internal Medicine, the team initially suggested that fish oil might help fistulas mature and prevent failure by blocking platelet aggregation, as well as decreasing blood viscosity, and promoting the widening of vessels (vasodilation).

In patients with chronic kidney disease undergoing creation of an AVF, three months’ treatment with fish oil at a dose of 4g per day did not reduce the composite primary outcome of AVF failure nor any of the individual components, which included AVF abandonment, thrombosis, and cannulation failure, assessed at 12 months," wrote he team.

RCT

Irish and her team recruited 567 patients from 35 dialysis centres in four countries (Australia, New Zealand, Malaysia and the UK) in to the RCT - with 536 patients included in the final analysis. Subjects received either 4g per day of fish oil, or 4g of olive oil as a placebo, delivered as two 1g capsules twice daily.

The fish oil supplements were Omacor capsules containing 46% eicosapentaenoic acid and 38% docosahexaenoic acid.

However, the researchers found no benefit to the supplementation. Blood tests showed subjects receiving fish oil supplements had increased omega-3 levels, confirming they were taking the capsules – but no other clinically relevant effects were apparent.

Indeed, those receiving fish oil showed the same 47% fistula failure rate as those receiving placebo.

The trial finished before reaching the planned recruitment target but was able to show that fish oil is unlikely to reduce the risk of AVF failure by 30%; results were consistent with, at best, a 14% RR reduction,” the authors added.

The authors wrote that it was unknown whether the levels of the fish oil fatty acids were insufficient to promote the expected effects.

However, the doses of eicosapentaenoic and docosahexaenoic acids used in the FAVOURED trial were higher than doses used in studies assessing [graft] outcomes, and studies in patients with chronic kidney disease using a comparable dose of fish oil achieved significant reductions in blood viscosity, platelet aggregation, and blood pressure consistent with biological effects,” they added.

Aspirin, too, showed a similar failure rate.

The proportion of new AVFs that failed within 12 months of surgery was nearly 50% and was not reduced by 12 weeks of fish oil supplementation or low-dose aspirin therapy. This study suggests that neither fish oil nor aspirin can be recommended for the prevention of AVF failure,” the authors wrote in their conclusion.

Source: JAMA Internal Medicine
Published online ahead of print, doi:10.1001/jamainternmed.2016.8029
Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis; A Randomized Clinical Trial
Authors: Irish AB, Viecelli AK, Hawley CM, Hooi L, Pascoe EM, Paul-Brent P, Badve SV, Mori TA, Cass A, Kerr PG, Voss D, Ong L, Polkinghorne KR 

Post a comment

Comment title *
Your comment *
Your name *
Your email *

We will not publish your email on the site

I agree to Terms and Conditions

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Related products